Skip to main content

Table 4 Number of patients with adverse events in the ETA+MTX and MTX groups according to study phase

From: Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

Phase

Group

MTX

ETA + MTX

Phase 1

7 patients (21%)

(11 AEs)

4 patients (11%)

(6 AEs)

Phase 2

3 patients (15%)

(3 AEs)

5 patients (11%)

(5 AEs)

Phase 3

3 patients (33%)

(3 AEs)

9 patients (17%)

(14 AEs)

  1. The table shows the number of patients with AE, (rate of patients with AE), (number of AE); AE adverse event, ETA Etanercept, MTX Methotrexate
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096